In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AnorMed Inc.

Division of Sanofi

Latest From AnorMed Inc.

Millennium Prospers Under Takeda--But Will Takeda Get Full Value?

In losing its autonomy as an independently traded entity, Millennium has finally gained the freedom to become a larger player in the oncology space. One year after being acquired by Takeda, the biotech must no longer demonstrate to Wall Street regular quarterly earnings from Velcade, its only product, while trying to fund additional trials and build its pipeline. The success of this new business model fashioned by Takeda for its acquisition is still an open question, but it could provide a winning formula for Big Pharma companies in dire need of rejuvenated pipelines.
BioPharmaceutical Business Strategies

Takeda/ Millennium: The Price is Right

Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
BioPharmaceutical North America

Stem Cell Therapies: Excitement Builds but Challenges Remain

With weak pharmaceutical pipelines and demand increasing for tailored medical approaches, adult and embryonic stem cell therapies are gaining ground as a therapeutic focus. Numerous companies are now active in this research and some observers estimate that the stem cell market could reach between $8.5 and $10 billion within the next ten years.

Activist Shareholders Complicate Buyout Math

The efforts of an increasingly vocal group of activist shareholders, including Carl Icahn, Matrix Asset Advisors, Third Point, ValueAct, and Baker Brothers Advisors, to flush out the interest of strategic buyers has become compelling and increasingly commonplace.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Michael J Abrams, PhD, Pres. & CEO
    Bill Adams, VP, Fin. & CFO
    Paul Brennan, VP, Bus. Dev.
    Gary Bridger, PhD, VP, R&D & CSO
  • Contact Info
  • AnorMed Inc.
    Phone: (604) 530-1057
    20353 64th Ave.
    Ste. 200
    Langley, V2Y 1N5